AKAMAI V – “How To” Induce Infringement of a Method of Treatment Claim
I have both been busy since the holiday season and frankly, uninspired by the case law that has appeared on the scene. Who can be enraptured by the fine points of standing when we are all speculating...
View ArticleSupreme Court Bars Laches Defense, Leaves Statute of Limitations in Patent Suits
One more Federal Circuit decisions bites the dust. Today, in SCA Hygiene Products AB v. First Quality Baby Products, LLC, the Supreme Court held that the equitable doctrine of laches (undue delay)...
View ArticleNovartis AG, LTS et al. v. Noven Pharmaceuticals, Inc. – Prior Judicial...
After Novartis’ patents were found nonobvious by the Fed. Cir., affirming the Delaware District Court, defendant Noven filed for inter partes review (IPR) of U.S. Pat. Nos. 6316023 and 6335031, on...
View ArticleFairchild (Taiwan) Corp. v. Power Integrations, Inc.
In my last post, I discussed estoppel in the context in inter partes review, in which defendant filed for IPR after losing in the courts. The Board found the claims-in-suit to be obvious. The Federal...
View Article“TC Heartland” Supreme Court Limits Venue in Patent Suits
Monday, in a unanimous opinion (Goresuch did not participate), the Supreme Court interpreted the patent venue statute (28 USC s. 1400(b)) to require that the phrase “where the defendant resides” be...
View ArticleChisum Patent Academy – Commentary on Impression Products v Lexmark...
This is a repost of commentary by Donald Chisum and Janice Muller of Chisum Patent Academy. In Impression Products, Inc. v. Lexmark International, Inc., No. 15-1189, — S. Ct. —-, 2017 WL 2322830 (May...
View ArticleJust When You Thought Things Couldn’t Get Worse Via The Application Of 101
On Friday, in Cleveland Clinic Foundation v. True Health Diagnostics, Appeal no. 2016-1766 (Fed. Cir., June 16, 2017), a Fed. Cir. panels of Judges Lourie, Reyna and Wallach (Reyna writing) held that...
View ArticleThe Cleveland Clinic v. True Health Diagnostics LLC – Time to Redefine...
Ariosa was a decision that essentially held that the novel discovery of a naturally-occurring phenomenon could not per se meet the Mayo/Alice requirement for an inventive concept, even though it was of...
View ArticleMillennium Pharm. v. Sandoz, Inc. – Revenge of the Chemical Judges
In the 2003 panel decision in Schering Corp. v. Geneva Pharm., Inc., the panel rejected “the contention that inherent anticipation requires recognition [of the claim element not found] in the prior...
View ArticleInequitable Conduct Intent Prong Due to Litigation Misconduct
In Regeneron Pharmaceuticals v. Merus N.V., Appeal No. 2016-1346 (Fed. Cir., July 27, 2017), a split three-judge panel of Prost, Wallach and Newman (Newman dissenting) affirmed the district court’s...
View ArticleHoneywell International, Inc. v. Mexichem Amanco Holdings – Revenge of the...
Before reading this post, please read my post of July 19, 2017 about Millennium Pharms. v. Sandoz, and you will “get” the title. Judges Lourie and Newman both dissented from refusal of the court to...
View ArticleAthena Diagnostics v. Mayo – Finessing the Correlations Trap?
In The Cleveland Clinic Foundation v. True Health Diagnostics, the Fed. Cir. panel held that a claim to a diagnostic method for determining a test subject’s risk for atherosclerotic cardiovascular...
View ArticleMallinckrodt v. Praxair – Innomax Method Patent Fails Alice/Mayo Test
On Tuesday, a Delaware district court judge ruled that a group of Mallinckrodt patents failed the Alice/(mostly)Mayo test as claiming a natural phenomenon. The patents are directed to a method of...
View ArticleSixteen Critical 2016-2017 Patentability & Validity Developments
This is a guest post from Janice M. Mueller of the Chisum Patent Academy. Below are highlights of the Critical Patentability & Validity Developments of 2016-2017. The Federal Circuit’s January...
View ArticleSea Change in IPR or Just an SOS? – Aqua Products, Inc. v. Matal
Sitting en banc, a fractured Federal Circuit (Appeal no. 2015-1177 (Fed. Cir., Oct. 4, 2017)) released 140+ pages comprising five separate opinions (7 Judges “concur in result”). The majority held...
View ArticleIn re Smith, International, Inc. – What’s a “Body” to Do?
In re Smith, International, Inc., Appeal no. 2016-2303 (Fed. Cir., Sept. 16, 2017)(”Smith”), the Fed. Cir. reversed the PTAB (that had affirmed the Examiner’s rejection of the claims) on the basis that...
View ArticleAli v. Carnegie Institution of Washington – Where Did Ali Go Off the Rails?
In view of the IP hornets’ nest stirred up by Judge Bryson’s ruling in Allergan and the St. Regis Mohawk Tribe v. Teva Pharm. Inc., Case No. 2:15-cv-1455-WCB (E.D. Tex. , Oct. 16, 2017), which may or...
View ArticleThings to be Thankful for in IP Wonderland
Apart from the carnage wrought by the ever-expanding scope of s. 101 rejections and the tightening of the written description requirement, there were still a number of events/trends in 2017 to applaud...
View ArticleThe Twelve §101 Precedential Decisions of 2017
This is a guest post from the Chisum Patent Academy. In 2017, Federal Circuit panels regularly addressed attacks on software patent claims as ineligible under the Alice “abstract idea” exception. The...
View ArticleAptalis Fails to “Surround’ Apotex’s Generic ER Tablet
Although non-precedential, Aptalis Pharmatech, Inc. v. Apotex, Inc., Appeal No. 2017-1344 (Fed. Cir., January 4, 2018) provides a useful outline of Phillips-type claim construction and requires a close...
View Article